Topic

drug compounding

4 articles on drug compounding in longevity medicine. View all news →

FDA: July 2026 Pharmacy Compounding Advisory Committee meeting

Peptide Therapy at Longevity Clinics: FDA Status and Safety Questions (2026)

What the FDA's July meeting did and did not change for BPC-157, TB-500, MOTS-c, Semax, Epitalon and other peptides marketed by longevity clinics.

peptide therapy BPC-157 FDA regulation
FDA: July 2026 Pharmacy Compounding Advisory Committee meeting

Peptide Therapy at Longevity Clinics: Why WLC Withdrew Its 2026 Ranking

WLC withdrew its 2026 peptide-clinic ranking because provider flags, marketing sources, dose tables, prices, and a claimed FDA reclassification did not support a safe recommendation.

peptide therapy drug compounding FDA regulation
NPR: The government may soon lift restrictions on some peptide treatments

FDA Peptide Reclassification 2026: Announcement vs Final Action

An HHS announcement prompted reports of a peptide reclassification. Later FDA records show why an announcement, compounding policy, drug approval, and clinical evidence are different questions.

peptide therapy FDA regulation drug compounding
Longevity Docs newsletter

'Back to Medicine' at Longevity Docs Cannes: A Peptide Traceability Checklist

Longevity Docs promotes evidence, supervision, and traceable peptide supply. FDA records show why patients and clinics must verify the ingredient, compounder, lot, and regulatory pathway.

peptide therapy drug compounding traceability